Welcome to our dedicated page for Mustang Bio news (Ticker: MBIO), a resource for investors and traders seeking the latest updates and insights on Mustang Bio stock.
Mustang Bio, Inc. (Nasdaq: MBIO) is a clinical-stage biopharmaceutical company developing cell therapies for difficult-to-treat cancers, and its news flow reflects both scientific progress and capital markets activity. The company focuses on CAR T-cell therapies and an HSV-1 oncolytic virus, with programs aimed at malignant glioma, recurrent glioblastoma (GBM), high-grade astrocytomas, and related brain tumors.
News about Mustang Bio often centers on pipeline milestones, including updates on MB-101, an IL13Rα2-targeted CAR T-cell therapy, and MB-108, an HSV-1 oncolytic virus. The company has reported U.S. Food and Drug Administration Orphan Drug Designations for MB-108 in malignant glioma and MB-101 in recurrent diffuse and anaplastic astrocytoma and glioblastoma. Mustang Bio also highlights the MB-109 regimen, which combines MB-101 and MB-108 to reshape the tumor microenvironment and potentially enhance CAR-T activity in recurrent GBM and high-grade astrocytomas.
Investors following MBIO news will also see listing and financing developments, such as reverse stock split announcements, Nasdaq compliance updates on minimum bid price and stockholders’ equity requirements, and details of public offerings and warrant exercises. These items provide context on Mustang Bio’s access to capital and its efforts to maintain its Nasdaq Capital Market listing.
This news page aggregates Mustang Bio’s press releases and related coverage, giving readers a single place to review regulatory designations, clinical trial updates, facility and operational changes, and securities offerings. For those tracking MBIO, revisiting this page can help monitor how Mustang Bio’s cell therapy programs and corporate actions evolve over time.
Mustang Bio (NASDAQ: MBIO) supports Rare Disease Day on February 28, aiming to enhance awareness of rare diseases. The company is committed to advancing treatments for conditions like X-linked severe combined immunodeficiency (XSCID) and blastic plasmacytoid dendritic cell neoplasm (BPDCN). Two pivotal clinical trials for XSCID are set to begin this year, RESTORE and SUSTAIN, targeting young patients and those with prior stem cell transplants. Mustang's initiatives also include partnerships with patient advocacy groups. The company acknowledges the challenges faced by individuals with rare diseases as they work towards potential cures.
Mustang Bio, a clinical-stage biopharmaceutical company (NASDAQ: MBIO), announced its CEO, Manuel Litchman, will participate in three upcoming virtual investor conferences in January 2021. These include the 10th Annual LifeSci Partners Corporate Access Event from January 6-14, the H.C. Wainwright Virtual BioConnect Conference on January 11, and the B. Riley Securities’ Virtual Oncology Investor Conference on January 21. Presentations will be available on Mustang's website for 30 days following the events. Mustang focuses on cell and gene therapies for cancers and rare diseases.
Mustang Bio (NASDAQ: MBIO) has initiated a Phase 1 clinical trial at City of Hope to evaluate the safety and feasibility of MB-101 (IL13Rα2-CAR T cells) in treating patients with leptomeningeal brain tumors, including glioblastoma, ependymoma, and medulloblastoma. The trial will involve up to 30 patients and will assess toxicity and survival at three months, with additional secondary endpoints. The therapy previously showed promising results, including a complete response in a glioblastoma patient. The trial aims to provide a potential new treatment for these difficult-to-treat cancers.
Mustang Bio (NASDAQ: MBIO) presented promising interim data for MB-106, a CD20-targeted CAR T cell therapy, at the 62nd ASH Annual Meeting. The therapy showcased an impressive 89% overall response rate and a 44% complete response rate among nine patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Safety data indicated no neurotoxicity and low incidence of cytokine release syndrome. Mustang plans to file an Investigational New Drug application in Q1 2021 to start a Phase 2 trial, expanding eligibility to include chronic lymphocytic leukemia patients.
Mustang Bio (NASDAQ: MBIO) will host a key opinion leader call on December 9, 2020, at 1:00 p.m. EST to present interim Phase 1/2 data on MB-106, an innovative CAR T cell therapy targeting relapsed or refractory B-cell non-Hodgkin lymphoma. The call will feature Drs. Mazyar Shadman and Brian Till from Fred Hutchinson Cancer Research Center, discussing clinical findings and a modified cell manufacturing process. Additionally, Mustang will provide a corporate update and address audience questions following the presentations.
Mustang Bio (NASDAQ: MBIO) received a positive opinion from the European Commission for Orphan Drug Designation for its lentiviral gene therapy targeting X-linked severe combined immunodeficiency (XSCID). This designation applies to both MB-107 and MB-207 therapies. Key advantages include protocol assistance and 10 years of market exclusivity in the EU. Mustang is preparing for pivotal clinical trials for these treatments and expects to initiate them soon. Additionally, an agreement with Minaris Regenerative Medicine enables GMP manufacturing for clinical trials in Europe.
Mustang Bio (NASDAQ: MBIO) has partnered with Minaris Regenerative Medicine for the GMP clinical manufacturing of its MB-107 lentiviral gene therapy targeting X-linked severe combined immunodeficiency (XSCID) in Europe. The collaboration will facilitate technology transfer and support clinical trials for this rare genetic disorder, which affects 1 in 225,000 births. MB-107 is currently in Phase 1/2 trials in the U.S. with plans for a pivotal trial in Europe. Mustang aims to provide this therapy to patients internationally, targeting topline data by late 2022.
Mustang Bio, Inc. (NASDAQ: MBIO) reported its third-quarter financial results for 2020, highlighting significant regulatory achievements. The FDA granted Rare Pediatric and Orphan Drug Designations for its gene therapy candidates MB-107 and MB-207 to treat X-linked severe combined immunodeficiency (XSCID). Mustang noted promising clinical progress in CAR T cell therapies, particularly with MB-106, showing efficacy without toxicity in non-Hodgkin lymphoma patients. Financially, Mustang's cash reserves decreased from $86.4 million to $76.3 million year-over-year, and the net loss increased to $13.0 million, or $0.23 per share.
Mustang Bio (NASDAQ: MBIO) announced that interim data on MB-106, a CAR T cell therapy for relapsed or refractory B-cell non-Hodgkin lymphoma, will be presented at the 62nd ASH Annual Meeting. The data includes responses from four patients treated after a manufacturing revision, showing two complete and one partial remission. The therapy demonstrated an encouraging safety profile, with no dose-limiting toxicities and only one case of cytokine release syndrome. Mustang aims to provide further updates on additional patients treated since the revision.
Mustang Bio (NASDAQ: MBIO) announced the presentation of promising data from a Phase 1 trial on MB-105, a CAR T therapy targeting prostate cancer. Conducted by Dr. Tanya Dorff at City of Hope, the trial showed a remarkable 94% reduction in prostate-specific antigen (PSA) in a 73-year-old male patient after failing eight prior therapies. The treatment resulted in near-complete reduction of metastasis and was manageable regarding cytokine release syndrome. Mustang's CEO expressed optimism for further trial progress and additional data expected in 2021.